آخر الأخبار لـ ARKG

The ARK Genomic Revolution ETF fell 8.84% to $51.75 on October 06, with assets under management of approximately $1.56 billion. The fund, which holds genomics and biotechnology equities, remains up 95.96% year-to-date despite the single-session decline.

The ARK Genomic Revolution ETF closed at $56.85 on October 05, gaining 5.28% on the day, with AUM of approximately $1.56 billion. The fund targets companies involved in genomics and biotechnology innovation. Its year-to-date return of 86.40% makes it one of the stronger performers in the thematic equity space this year.

The ARK Genomic Revolution ETF closed at $53.53 on September 24, gaining 5.13% on the day, with AUM of approximately $1.56 billion. The fund tracks genomics and biotechnology-focused equities. The single-day gain extends a year-to-date advance of 75.77%, making it one of the stronger-performing thematic ETFs of the year.

The ARK Genomic Revolution ETF (ARKG) fell 4.47% to $47.64 on August 30, with AUM of approximately $1.56 billion. The fund's year-to-date return stands at 64.45%. ARKG holds equities focused on genomics, gene editing, and related biotechnology themes, and despite the session's decline, it has been among the stronger-performing thematic ETFs for the year.

The ARK Genomic Revolution ETF (ARKG) declined 4.47% to $47.64 on August 29, with AUM of approximately $1.56 billion. Year-to-date the fund remains up 64.45%. ARKG is an actively managed ETF focused on genomics and biotechnology companies, a sector known for elevated single-session price moves.

The ARK Genomic Revolution ETF (ARKG) fell 4.47% to $47.64 on August 28, with AUM of approximately $1.56 billion. The actively managed fund focuses on companies involved in genomics, gene editing, and related biotechnology; the session decline left its substantial year-to-date gain of 72.14% largely intact.

ARK Genomic Revolution ETF (ARKG) advanced 4.27% to $50.06 on August 25, with AUM of approximately $1.6 billion. The fund has now gained 65.72% year-to-date, making the day's move incremental relative to a strong broader run. ARKG is an actively managed ETF focused on companies involved in genomics, gene editing, and related biotechnology.

ARK Genomic Revolution ETF closed at $47.73 on August 19, gaining 10.46% on the day, with AUM of approximately $1.56 billion. The fund tracks genomics and biotechnology equities. The single-day move extends a year-to-date gain of 49.15%, making it one of the stronger performers in the thematic equity space in 2025.